CA3233706A1 - Inhibiteurs d'inflammation et de metastase de cancer a base de nanomateriaux mno - Google Patents

Inhibiteurs d'inflammation et de metastase de cancer a base de nanomateriaux mno Download PDF

Info

Publication number
CA3233706A1
CA3233706A1 CA3233706A CA3233706A CA3233706A1 CA 3233706 A1 CA3233706 A1 CA 3233706A1 CA 3233706 A CA3233706 A CA 3233706A CA 3233706 A CA3233706 A CA 3233706A CA 3233706 A1 CA3233706 A1 CA 3233706A1
Authority
CA
Canada
Prior art keywords
nucleic acid
mno
nanoparticles
curcumin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233706A
Other languages
English (en)
Inventor
Kam W. Leong
Yiling ZHONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NewSouth Innovations Pty Ltd
Columbia University in the City of New York
Original Assignee
NewSouth Innovations Pty Ltd
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NewSouth Innovations Pty Ltd, Columbia University in the City of New York filed Critical NewSouth Innovations Pty Ltd
Publication of CA3233706A1 publication Critical patent/CA3233706A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ceramic Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Les fixateurs d'acide nucléique à base de nanoparticules d'oxyde de manganèse anioniques sont des fixateurs anioniques biodégradables à faible cytotoxicité, qui peuvent se fixer (se lier) à des acides nucléiques acellulaires (par exemple, un ARNsb, un ARNdb et un ADN non méthylé extracellulaires), fournissant un traitement pour diverses conditions médicales. Le composant principal du fixateur est l'oxyde de manganèse, qui peut être synthétisé à l'aide d'un composé manganèse (par exemple, l'acétate de manganèse) et d'un acide (par exemple, l'acide tannique) à haute température (par exemple 100-150 °C). La synthèse peut être réalisée par mélange d'un composé manganèse et d'un acide dans de l'eau, ce qui forme un mélange, qui est agité, chauffé et amené à refroidir. Les nanoparticules d'oxyde de manganèse anioniques sont extraites du mélange refroidi. La taille typique des nanomatériaux résultants est comprise entre 30 et 100 nm; le potentiel zêta des nanomatériaux ainsi préparés est d'environ -20 mV. Les nanoparticules ont diverses utilisations, notamment leur administration à un sujet pour traiter une inflammation ou pour traiter le cancer.
CA3233706A 2021-09-30 2022-09-30 Inhibiteurs d'inflammation et de metastase de cancer a base de nanomateriaux mno Pending CA3233706A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163250311P 2021-09-30 2021-09-30
US63/250,311 2021-09-30
US202263305340P 2022-02-01 2022-02-01
US63/305,340 2022-02-01
PCT/US2022/077427 WO2023056470A1 (fr) 2021-09-30 2022-09-30 Inhibiteurs d'inflammation et de métastase de cancer à base de nanomatériaux mno

Publications (1)

Publication Number Publication Date
CA3233706A1 true CA3233706A1 (fr) 2023-04-06

Family

ID=85783698

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233706A Pending CA3233706A1 (fr) 2021-09-30 2022-09-30 Inhibiteurs d'inflammation et de metastase de cancer a base de nanomateriaux mno

Country Status (4)

Country Link
EP (1) EP4408439A4 (fr)
JP (1) JP2024537825A (fr)
CA (1) CA3233706A1 (fr)
WO (1) WO2023056470A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116135236B (zh) * 2023-03-09 2024-07-19 东华大学 一种光热纤维复合水凝胶敷料及其制备方法
CN119971070A (zh) * 2025-02-12 2025-05-13 山东第一医科大学附属眼科医院(山东省眼科医院) 一种光热光动力一体化抗菌纳米药物及其制备方法和在制备生物膜相关性角膜炎药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361188B2 (en) * 2009-04-03 2013-01-29 Indian Institute Of Science Methods for preparing metal and metal oxide nanoparticles
US10780164B2 (en) * 2014-04-03 2020-09-22 The Governing Council Of The University Of Toronto Multifunctional nanoparticle compositions and uses thereof
CN109833476A (zh) * 2017-11-28 2019-06-04 深圳先进技术研究院 一种靶向特异性响应肿瘤微环境纳米光敏剂及其制备方法和应用
CN108030933B (zh) * 2017-12-13 2020-06-19 北京工商大学 一种高灵敏度双模态磁共振造影剂及其制备方法
WO2019164872A2 (fr) * 2018-02-20 2019-08-29 University Of Florida Research Foundation, Inc. Composition et procédé de ciblage de cellules tueuses naturelles en immunothérapie pour surmonter la suppression tumorale avec des nanoparticules de dioxyde de manganèse
CN114796598A (zh) * 2022-05-06 2022-07-29 南京工业大学 一种促难愈性创面愈合的抗菌水凝胶及应用

Also Published As

Publication number Publication date
WO2023056470A1 (fr) 2023-04-06
JP2024537825A (ja) 2024-10-16
EP4408439A4 (fr) 2025-07-30
EP4408439A1 (fr) 2024-08-07

Similar Documents

Publication Publication Date Title
Liang et al. Circulating microRNAs as emerging regulators of COVID-19
Lee et al. The role of microRNAs in acute respiratory distress syndrome and sepsis, from targets to therapies: a narrative review
Wang et al. Endothelial cell signaling and ventilator-induced lung injury: molecular mechanisms, genomic analyses, and therapeutic targets
Nofi et al. Chromatin-associated molecular patterns (CAMPs) in sepsis
Zhu et al. Myeloid cell‐specific topoisomerase 1 inhibition using DNA origami mitigates neuroinflammation
Maggi et al. A pathogenic integrated view explaining the different endotypes of asthma and allergic disorders
CA3233706A1 (fr) Inhibiteurs d'inflammation et de metastase de cancer a base de nanomateriaux mno
Popotas et al. Sex-related immunity: could Toll-like receptors be the answer in acute inflammatory response?
Falck‐Jones et al. Respiratory and systemic monocytes, dendritic cells, and myeloid‐derived suppressor cells in COVID‐19: Implications for disease severity
Poux et al. A single-stranded oligonucleotide inhibits toll-like receptor 3 activation and reduces influenza A (H1N1) infection
Renkonen et al. Expression of Toll‐like receptors in nasal epithelium in allergic rhinitis
Liu et al. Critical contributions of protein cargos to the functions of macrophage-derived extracellular vesicles
JP2019023193A (ja) がんを治療する方法
Lin et al. Microarray analysis of infectious bronchitis virus infection of chicken primary dendritic cells
Valverde et al. Non‐coding RNA LINC01010 regulates macrophage polarization and innate immune functions by modulating NFκB signaling pathway
WO2023056467A1 (fr) Inhibiteurs à base de nanomatériau mno d'inflammation et de réplication virale de sars-cov-2
Bao et al. PVC Nanoplastics Exposure Exacerbates Asthma through R‐Loop Accumulation and Subsequent STING Activation in Macrophages
US20250255984A1 (en) Mno nanomaterial based inhibitors of inflammation and cancer metastasis
US20240390417A1 (en) Mno nanomaterial based inhibitors of inflammation and sars-cov-2 viral replication
Lim et al. Absence of c-Maf and IL-10 enables type I IFN enhancement of innate responses to LPS in alveolar macrophages
Clanchy et al. Modulation of toll-like receptor function has therapeutic potential in autoimmune disease
Easley et al. Chronic alcohol use primes bronchial cells for altered inflammatory response and barrier dysfunction during SARS-CoV-2 infection
Zhuang et al. Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
Zheng et al. Interleukin-1 prevents SARS-CoV-2-induced membrane fusion to restrict viral transmission via induction of actin bundles
Hoover et al. N‐Dihydrogalactochitosan Drives Conventional and Alternative Activations of STING to Synergize Type I IFN and IL‐1β Productions for Antitumor Immunity.

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250117

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251027